

Protein Quantification for Biologics Development

Protein quantification is vital for developing new biologics, revealing how therapeutic candidates behave and perform. Measuring protein levels enables early evaluation of potency, safety, and pharmacokinetics, helping to filter out weak candidates before clinical trials. This data-driven approach streamlines the path from discovery to the clinic, accelerating the delivery of life-changing treatments to patients

All assays are developed and validated according to study-specific requirements.

Platforms	Advantages	Applications
ELISA (Enzyme-linked Immunosorbent Assay)	Reliable high-throughput screening with optimized cost per sample and high reproducibility	Quantification of proteins in cell lysates, tissue extracts, and biological fluids for biomarker discovery, pharmacokinetics, and drug efficacy studies
ECLIA (ElectroChemiluminescence ImmunoAssay)	High sensitivity, low sample volume, and advanced multiplexing capabilities	Multiplex biomarker and cytokine analysis in complex matrices to assess drug effects on signaling pathways
Jess (Automated Western Blot)	Fast, high-throughput alternative to Western blot (~3 h vs. ~72 h), enabling precise quantification and multiplexing via chemiluminescence and fluorescence	Protein expression profiling, target validation, and analysis of protein modifications in cell and tissue lysates
Biolayer Interferometry	Label-free, real-time analysis of molecular interactions	Characterization of binding kinetics and affinity of antibodies and therapeutic candidates using a high-throughput dip-and-read method for rapid screening